We use cookies to give you a better experience on our website. Learn more about how we use cookies and how you can select your preferences.
Vaxxas – needle-free vaccines
Vaxxas has used the R&D Tax Incentive (R&DTI) to develop less invasive vaccine delivery technology that creates a more potent immune response.
The R&D Tax Incentive helped attract further investment in our company and open up more chances for collaboration with large pharma companies, universities and philanthropic organisations around the world.
Company profile
Company: Vaxxas Pty Ltd
Sector: Biotechnology
Location: Brisbane, Queensland
Profile: Vaxxas is a medical technology startup located in Brisbane, revolutionising the way vaccines are delivered. While vaccinations have historically been given using needles, through the R&DTI Vaxxas has been able to develop their Nanopatch™ – a needle-free vaccine delivery technology with improved immune performance.